Full Description
This treatise examines the value of neoadjuvant chemotherapy for survival or bladder preservation. Using a multidisciplinary approach, it describes the results of clinical trials involving 35 patients and offers conclusions that can be compared with other studies and may reveal alternative methods to chemotherapy. Specifically covered are criteria for neoadjuvant chemotherapy eligibility, the extent of staging and restaging procedures, uniform definitions for the assessment of response, and the numerous types and extent of locoregional therapy following chemotherapy.
Contents
Partial table of contents:; STATE OF THE ART LECTURES; Chemotherapy for Invasive Bladder Tumors (H. Scher); The Role of Surgery in Initial Staging and Follow Up (H. Herr); Trial Design and Statistics (O. Dalesio); RANDOMIZED CLINICAL TRIALS; The Integration of Chemotherapy, Radiotherapy, and Transurethral Surgery in Bladder-Sparing Approaches for Patients with Invasive Tumors (W. Shipley, et al.); NON-RANDOMIZED CLINICAL TRIALS; Neoadjuvant Medium-Dose Methotrexate, Cisplatin in Category T3b-T4a (NOMO) Bladder Cancer (G. Pizzocaro, et al.); Neo-Adjuvant Intra-Arterial Chemotherapy in Locally Advanced Bladder Cancer (G. Chechile, et al.); Bladder Sparing Approach to Muscle Invasive Carcinoma of the Bladder (R. Marino & Z. Wajsman); ASSESSMENT OF RESPONSE; Evaluation of Tumor Response and Prognostic Factors in Patients with Bladder Cancer Undergoing Combined Radiotherapy and Chemotherapy (G. Jakse, et al.); Combination Chemotherapy Followed by Surgery: The Case for a Marker Lesion (L. Denis, et al.); Index.
